Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lori Berk

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Cold Spring Harbor Protocols|July 4, 2012
Dimerizer-mediated regulation of gene expression in vivoVictor M Rivera, Lori Berk, Tim Clackson
Cold Spring Harbor Protocols|July 4, 2012
Dimerizer-mediated regulation of gene expressionVictor M Rivera, Lori Berk, Tim Clackson
Cold Spring Harbor Protocols|July 4, 2012
Dimerizer-mediated regulation of gene expression in vitroVictor M Rivera, Lori Berk, Tim Clackson
Cancer Chemotherapy and Pharmacology|January 11, 2012
Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trialLori Berk, Monica M Mita, Jeff Kreisberg, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 30, 2005
Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned ratsLaura M Sanftner, Victor M Rivera, Brian M Suzuki, et al.
Cancer Chemotherapy and Pharmacology|November 1, 2011
Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trialDavid A Reardon, Patrick Y Wen, W K Alfred Yung, et al.
Molecular Cancer Therapeutics|April 13, 2011
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimensVictor M Rivera, Rachel M Squillace, David Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignanciesChristine M Hartford, Apurva A Desai, Linda Janisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabineAntonella Perotti, Alberta Locatelli, Cristiana Sessa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomasSant P Chawla, Arthur P Staddon, Laurence H Baker, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Cold Spring Harbor Protocols|July 4, 2012
Dimerizer-mediated regulation of gene expression in vivoVictor M Rivera, Lori Berk, Tim Clackson
Cold Spring Harbor Protocols|July 4, 2012
Dimerizer-mediated regulation of gene expressionVictor M Rivera, Lori Berk, Tim Clackson
Cold Spring Harbor Protocols|July 4, 2012
Dimerizer-mediated regulation of gene expression in vitroVictor M Rivera, Lori Berk, Tim Clackson
Cancer Chemotherapy and Pharmacology|January 11, 2012
Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trialLori Berk, Monica M Mita, Jeff Kreisberg, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 30, 2005
Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned ratsLaura M Sanftner, Victor M Rivera, Brian M Suzuki, et al.
Cancer Chemotherapy and Pharmacology|November 1, 2011
Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trialDavid A Reardon, Patrick Y Wen, W K Alfred Yung, et al.
Molecular Cancer Therapeutics|April 13, 2011
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimensVictor M Rivera, Rachel M Squillace, David Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignanciesChristine M Hartford, Apurva A Desai, Linda Janisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabineAntonella Perotti, Alberta Locatelli, Cristiana Sessa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomasSant P Chawla, Arthur P Staddon, Laurence H Baker, et al.
Pageof 2